Abivax is focused on developing innovative treatments that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is focused on developing innovative treatments that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224...
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約